Yulong Biotechnology

Yulong Biomedical Group originated in 2002, dedicated to the application of high-precision and advanced molecular biology technologies, information technology, automation control technology, and laboratory medicine technology in human health. Always committed to "caring for life, promoting health" and pursuing the establishment of industry standards, after more than ten years of development and growth, adhering to the business philosophy of "continuous innovation, sustainable development", the foundation of today's achievements has been accomplished.
The group owns national "***" enterprises, the domestic *** "National Engineering Laboratory for Immunodiagnostic Reagents", a precision diagnostics platform - the National Gene Testing Technology Application Demonstration Center, a national high-tech industrialization demonstration project, Shanghai high-tech enterprises, Shanghai patent work demonstration enterprises, and Shanghai intellectual property demonstration enterprises, forming three major businesses: "diagnostic products", "medical laboratory testing", and "health management", and constructing the grand blueprint of the "big health industry" of Yulong Biomedical Group. It has successively undertaken multiple *** key projects such as the "863 Major Special Project", possessing 218 patented technologies and 109 authorized patents, ranking at the * position.
Yulong Biotechnology has an internationally advanced R&D center and production base, establishing eight modern biotechnology platforms including biochips, automated instruments, bioinformatics, biosensors, genetic engineering, cell engineering, antibody libraries, and protein purification, forming a comprehensive R&D and production system for diagnostic products, raw materials, and supporting instruments. It has independently developed quantitative detection systems for multi-tumor markers in both men and women, a series of immunochemiluminescence quantitative detection systems, a series of gene detection systems, LCT liquid-based cytology detection systems, a series of biochemical detection systems, urine detection systems, and CTC liquid biopsy systems. These include the most advanced in vitro precision diagnostic technologies and have received multiple national, provincial, and ministerial awards.
Yulong Medical Laboratory is committed to the clinical application and technological innovation of medical diagnostic technologies, building a comprehensive and systematic diagnostic technology platform, including a *** gene testing technology application demonstration center covering prenatal screening, personalized medication, and gene sequencing, providing precise and timely diagnostic results and treatment basis for clinical diagnosis of various diseases. It is strictly managed according to ISO15189, U.S. CAP certification, and other international authoritative standards. It owns the first forensic identification institute in Shanghai established on the basis of an independent medical laboratory, capable of providing DNA paternity testing and forensic biological evidence identification services. In 2014, Yulong Medical Laboratory signed an agreement with the Health and Family Planning Commission of Xuhui District, Shanghai, to jointly build a regional medical laboratory center and establish a standardized information platform with all health service centers in the district. Currently, Yulong Medical Laboratory has reached cooperation consensus with multiple local governments and health and family planning commissions in Jiangsu, Shandong, Anhui, and other places, undertaking various medical institutions within their jurisdictions and jointly building regional medical laboratory centers, providing internationally advanced medical laboratory testing services, significantly improving the technical level of grassroots medical testing, and providing strong support for the implementation of hierarchical diagnosis and treatment.
Yulong Health is committed to building a domestic *** health management service platform, utilizing authoritative Internet+ and Yulong big data platforms to provide personalized health management including health check-ups, various genetic tests, sub-health management, early disease intervention, precision medicine, international medical guidance, green medical channels, and other one-stop full-lifecycle private customized services. The Yulong Health platform can provide analysis for corporate and institutional clients on projects such as doctor work assistants, electronic health records, and insurance data, helping medical and health institutions and insurance companies improve work efficiency and service quality; simultaneously, the platform provides personalized medical and health plans and disease risk assessments for individual clients, helping customers shift from a model of overdrawing health and fighting disease to a new health model of caring for health and preventing disease.
With the goal of becoming a leading enterprise in the big health industry, and with diagnostic products, medical laboratory testing, and health management as the core business structure, the full industry chain picture of "Yulong Big Health" is gradually unfolding.